An open-label, non-randomized, pharmacokinetic and safety study of multiple oral doses of GW679769 in subjects with hepatic impairment.

Trial Profile

An open-label, non-randomized, pharmacokinetic and safety study of multiple oral doses of GW679769 in subjects with hepatic impairment.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Casopitant (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Oct 2008 Actual start date changed from Apr 2006 to Dec 2005 as reported by Clinicaltrials.gov.
    • 04 Dec 2007 Status changed from recruiting to completed.
    • 07 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top